We are live on ! Find out more
APGN

Apexigen, Inc. Common Stock
APGN

Delisted

APGN was delisted on the 22nd of August, 2023.

Back to rankings

40 hedge funds and large institutions have $33.2M invested in Apexigen, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

5% more funds holding

Funds holding: 38 → 40 (+2)

2% more capital invested

Capital invested by funds: $32.5M → $33.2M (+$687K)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
40
Holders Change
+2
Holders Change %
+5.26%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$2.65M
2
MSU
Mizuho Securities USA
New York
+$915K
3
Goldman Sachs
Goldman Sachs
New York
+$383K
4
EAM
Exos Asset Management
New York
+$355K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$180K

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$3.83M
2
BCM
Basso Capital Management
Connecticut
-$1.24M
3
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$983K
4
LSC
Logan Stone Capital
Illinois
-$675K
5
LA
Linden Advisors
New York
-$624K
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
26
Janus Henderson Group
United Kingdom
$168K +$167K +16,697 New
Walleye Trading
27
Walleye Trading
New York
$164K – – –
Millennium Management
28
Millennium Management
New York
$151K -$182K -18,170 -55%
OCAM
29
Owl Creek Asset Management
New York
$151K +$150K +15,000 New
HF
30
HRT Financial
New York
$150K +$150K +14,952 New
CC
31
Centiva Capital
New York
$122K +$122K +12,140 New
DWM
32
Dakota Wealth Management
Florida
$110K – – –
GCWM
33
Graham Capital Wealth Management
District of Columbia
$110K +$110K +10,945 New
UBS Group
34
UBS Group
Switzerland
$47K +$4.75K +474 +11%
BHWM
35
Beaird Harris Wealth Management
Texas
$8K – – –
TRCT
36
Tower Research Capital (TRC)
New York
$2K -$1K -100 -40%
APC
37
Aspire Private Capital
North Carolina
$2K – – –
Osaic Holdings
38
Osaic Holdings
Arizona
$2K – – –
PFS
39
Prospera Financial Services
Texas
$2K +$2.01K +200 New
KC
40
Kepos Capital
New York
– -$3.83M -382,289 Closed
LSC
41
Logan Stone Capital
Illinois
– -$675K -67,416 Closed
LA
42
Linden Advisors
New York
– -$624K -62,282 Closed
Walleye Capital
43
Walleye Capital
New York
– -$146K -14,536 Closed
GCIA
44
Gabelli & Co Investment Advisers
New York
– -$111K -11,100 Closed
PCM
45
Pinz Capital Management
New York
– -$104K -10,391 Closed
GF
46
Gabelli Funds
New York
– -$102K -10,229 Closed
1
2

APGN Hedge Fund Activity: Q1 2022 in Review

40 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q1 2022, worth a combined $33.2M — up 2.1% from $32.5M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new APGN positions and 7 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Glazer Capital LLC, adding an estimated $2.65M. The largest seller was Kepos Capital, exiting entirely with an estimated $3.83M sold.

  • 40 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q1 2022, up from 38 in Q4 2021.
  • Funds reported $33.2M of Apexigen, Inc. Common Stock stock for Q1 2022, up 2.1% quarter-over-quarter.
  • 11 funds opened new Apexigen, Inc. Common Stock positions in Q1 2022 and 7 closed out, a net change of +4 holders.
  • The largest Apexigen, Inc. Common Stock buyer in Q1 2022 was Glazer Capital LLC, an estimated $2.65M added.
  • The largest Apexigen, Inc. Common Stock seller in Q1 2022 was Kepos Capital, an estimated $3.83M sold.

Based on aggregated 13F filings for Q1 2022.